NMTC vs. MDAI, FEMY, AKLI, RVP, IINN, ICU, LYRA, LNSR, MODD, and PYPD
Should you be buying NeuroOne Medical Technologies stock or one of its competitors? The main competitors of NeuroOne Medical Technologies include Spectral AI (MDAI), Femasys (FEMY), Akili (AKLI), Retractable Technologies (RVP), Inspira Technologies Oxy B.H.N. (IINN), SeaStar Medical (ICU), Lyra Therapeutics (LYRA), LENSAR (LNSR), Modular Medical (MODD), and PolyPid (PYPD). These companies are all part of the "surgical & medical instruments" industry.
Spectral AI (NASDAQ:MDAI) and NeuroOne Medical Technologies (NASDAQ:NMTC) are both small-cap medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their risk, analyst recommendations, community ranking, earnings, dividends, media sentiment, valuation, profitability and institutional ownership.
NeuroOne Medical Technologies has lower revenue, but higher earnings than Spectral AI.
Spectral AI has a beta of 0.61, meaning that its share price is 39% less volatile than the S&P 500. Comparatively, NeuroOne Medical Technologies has a beta of 0.82, meaning that its share price is 18% less volatile than the S&P 500.
In the previous week, Spectral AI had 5 more articles in the media than NeuroOne Medical Technologies. MarketBeat recorded 6 mentions for Spectral AI and 1 mentions for NeuroOne Medical Technologies. NeuroOne Medical Technologies' average media sentiment score of 0.49 beat Spectral AI's score of 0.00 indicating that Spectral AI is being referred to more favorably in the media.
Spectral AI presently has a consensus target price of $4.00, indicating a potential upside of 131.21%. NeuroOne Medical Technologies has a consensus target price of $2.20, indicating a potential upside of 92.98%. Given NeuroOne Medical Technologies' higher probable upside, research analysts plainly believe Spectral AI is more favorable than NeuroOne Medical Technologies.
Spectral AI has a net margin of 0.00% compared to Spectral AI's net margin of -478.41%. NeuroOne Medical Technologies' return on equity of 0.00% beat Spectral AI's return on equity.
NeuroOne Medical Technologies received 62 more outperform votes than Spectral AI when rated by MarketBeat users. However, 100.00% of users gave Spectral AI an outperform vote while only 71.59% of users gave NeuroOne Medical Technologies an outperform vote.
67.1% of Spectral AI shares are held by institutional investors. Comparatively, 16.1% of NeuroOne Medical Technologies shares are held by institutional investors. 56.7% of Spectral AI shares are held by insiders. Comparatively, 7.5% of NeuroOne Medical Technologies shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.
Summary
Spectral AI beats NeuroOne Medical Technologies on 10 of the 14 factors compared between the two stocks.
Get NeuroOne Medical Technologies News Delivered to You Automatically
Sign up to receive the latest news and ratings for NMTC and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding NMTC and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
NeuroOne Medical Technologies Competitors List
Related Companies and Tools
